These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2247484)

  • 21. High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow.
    Brockstein BE; Williams SF
    Stem Cells; 1996 Jan; 14(1):79-89. PubMed ID: 8820954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Supportive therapy with xenogenous peptides in patients with metastatic breast cancer undergoing aggressive chemotherapy (modified AC-protocol): a prospective, randomized double-blind study].
    Lange OF
    Onkologie; 1987 Jun; 10(3 Suppl):40-3. PubMed ID: 3309762
    [No Abstract]   [Full Text] [Related]  

  • 23. Neoadjuvant chemotherapy for locally advanced breast cancer.
    Specht J; Gralow JR
    Semin Radiat Oncol; 2009 Oct; 19(4):222-8. PubMed ID: 19732686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
    Huang EH; Tucker SL; Strom EA; McNeese MD; Kuerer HM; Buzdar AU; Valero V; Perkins GH; Schechter NR; Hunt KK; Sahin AA; Hortobagyi GN; Buchholz TA
    J Clin Oncol; 2004 Dec; 22(23):4691-9. PubMed ID: 15570071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant-preoperative-chemotherapy for breast cancer--preliminary report of the Vancouver trial.
    Ragaz J; Baird R; Rebbeck P; Coldman A; Goldie J
    Prog Clin Biol Res; 1985; 201():77-87. PubMed ID: 3912768
    [No Abstract]   [Full Text] [Related]  

  • 26. Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials.
    Anderson JR; Cain KC; Gelber RD; Gelman RS
    Cancer Treat Rep; 1985 Oct; 69(10):1139-46. PubMed ID: 3899355
    [No Abstract]   [Full Text] [Related]  

  • 27. Surgery, kinetics and biological considerations in planning adjuvant therapy protocols.
    Forbes JF
    Prog Clin Biol Res; 1990; 354A():133-46. PubMed ID: 2247485
    [No Abstract]   [Full Text] [Related]  

  • 28. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience.
    Buzdar AU; Singletary SE; Booser DJ; Frye DK; Wasaff B; Hortobagyi GN
    Surg Oncol Clin N Am; 1995 Oct; 4(4):715-34. PubMed ID: 8535907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Some prognostic factors in the combined therapy of locally advanced breast cancer].
    Voznyĭ EK; Kharchenko VP; Gurov SN; Dobrovol'skaia NIu; Bol'shakova SA
    Vopr Onkol; 2000; 46(6):732-6. PubMed ID: 11219949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant chemotherapy in stage III breast cancer.
    Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD
    Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trials referral resource. Adjuvant therapy of breast cancer.
    Cheson BD
    Oncology (Williston Park); 1989 Jun; 3(6):70-1, 74-5, 78. PubMed ID: 2534915
    [No Abstract]   [Full Text] [Related]  

  • 32. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment.
    Glück S; Ross AA; Layton TJ; Ostrander AB; Goldstein LC; Porter K; Ho AD
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):316-23. PubMed ID: 9502299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose chemotherapy with AHPCS for the treatment of breast cancer. The University of Colorado results.
    Cagnoni PJ; Shpall EJ; Bearman SI; Ross M; Jones RB
    Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S26-9. PubMed ID: 8899166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant therapy in breast cancer.
    Robert NJ
    Obstet Gynecol Clin North Am; 1994 Dec; 21(4):693-707. PubMed ID: 7731642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials.
    Mietlowski W; Wang J
    Contemp Clin Trials; 2007 Sep; 28(5):674. PubMed ID: 17449334
    [No Abstract]   [Full Text] [Related]  

  • 36. [Development of lung cancer following combined treatment of breast cancer].
    Vazhenin AV; Abdulina NA; Kuznetsova LV; Kondrat'eva LI
    Vopr Onkol; 1987; 33(3):79-80. PubMed ID: 3564376
    [No Abstract]   [Full Text] [Related]  

  • 37. [Adjuvant systemic therapy in breast carcinoma in the 1990s: status of things and open questions].
    Goldhirsch A; Neuenschwander H; Castiglione M; Senn HJ; Cavalli F
    Schweiz Med Wochenschr; 1990 Nov; 120(47):1771-83. PubMed ID: 2255883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
    Rouzier R; Pusztai L; Garbay JR; Delaloge S; Hunt KK; Hortobagyi GN; Berry D; Kuerer HM
    Cancer; 2006 Oct; 107(7):1459-66. PubMed ID: 16948128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-operative therapy of breast cancer: rationale for adjuvant chemotherapy.
    Butler WM
    J S C Med Assoc; 1984 Jan; 80(1):15-6. PubMed ID: 6371378
    [No Abstract]   [Full Text] [Related]  

  • 40. Mechanisms of hormone and cytotoxic drug interactions in the development and treatment of breast cancer.
    Clarke R; Lippman ME; Dickson RB
    Prog Clin Biol Res; 1990; 322():243-78. PubMed ID: 2154757
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.